Adaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $15.00

Adaptive Biotechnologies (NASDAQ:ADPT – Get Rating) had its target price lifted by Piper Sandler from $14.00 to $15.00 in a report released on Monday morning, The Fly reports. A number of other analysts also recently issued reports on ADPT. Credit Suisse Group reiterated an underperform rating and issued a $7.00 price target on shares of […]

Related Keywords

Chad ,Julie Rubinstein ,Piper Sandler ,R Mark Adams ,Harlan Robins ,Meeder Asset Management Inc ,Financial Services Group Inc ,Adaptive Biotechnologies Corp ,Morgan Stanley ,Manchester Capital Management ,Allspring Global Investments Holdings ,Credit Suisse Group ,Adaptive Biotechnologies ,Get Rating ,Suisse Group ,President Julie Rubinstein ,Mark Adams ,Asset Management ,Capital Management ,Global Investments Holdings ,Services Group ,Chad Robins ,Chris Carlson ,Adaptive Biotechnologies Daily ,Nasdaq Adpt ,Adpt ,Medical ,Boost Price Target ,